

Technical Analysis

Analyst(s)

Greater China Research Team
research-hk@uobkh.com

Tham Mun Hon, CFA
munhon.tham@uobkh.com
+852 2236 6799



HKT Trust and HKT (6823 HK)

Last price: HK\$12.29
Support levels: HK\$11.94/HK\$11.30
Resistance levels: HK\$12.58/HK\$12.71

Price executed a clear rejection at its previous price high resistance zone, resulting in the formation of a distinct lower high. The RSI has fallen below its neutral 50-midline and continues to slope downward. As long as counter-trend rallies remain strictly capped below this overhead resistance ceiling, we could expect continued downward expansion towards lower support targets.

Average timeframe: Around two weeks.



Sichuan Kelun-Biotech Biopharmaceutical (6990 HK)

Last price: HK\$466.00
Support levels: HK\$423.60/HK\$379.40
Resistance levels: HK\$502.00/HK\$514.50

Price executed a retest into its gap resistance zone, where overhead supply completely capped counter-trend advances. The RSI remains firmly established below its neutral 50-midline and continues to slope downward. As long as counter-trend rallies remain strictly capped below this gap resistance, we see a continued downward expansion towards lower support targets.

Average timeframe: Around two weeks.

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."